Pro Medicus Limited Full-Year Results
20 August 2020; Company Announcement - Pro Medicus Limited Full Year Results - Acrobat pdf 118k Highlights Strong growth continues despite restrictions of COVID-19 Revenue from underlying operations $56.8m – up 23.9% Underlying profit before tax $30.2m – up 33.4% Net profit after tax $23.1m – up 20.7% Margins increase to 52.5% Cash reserves $43.4m – up 34.3% Strong balance sheet - No debt Fully franked final dividend 6c per share. Total FY20 dividend up 14.3%. Three key contracts announced during the period Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a full- year net profit of $23.1m for the 12 months to the end of June 2020, 20.7% higher than for the previous corresponding period. Underlying profit before tax, which excludes a $3.0m one-off capital sale to the German government in the previous period, was $30.24m, an increase of 33.4%. Revenue from underlying operations, increased by 23.9% to $56.8m. There was solid growth in key jurisdictions – North America (up 23.7%) and Australia (up 19.2%) – while revenue from European operations fell 37.7%, largely as a result of the one-off sale to the German government in the previous period. The company's cash reserves at 30 June 2020 were $43.4m, a rise of 34.3%. Pro Medicus announced a final fully franked dividend of 6c per share, taking total dividends for the year to 12c per share. The company remains debt-free. During the year Pro Medicus announced three key contract wins: Ohio State University, November 2019 – a $9m five-year contract with the Ohio State University Wexner Medical Center, a large multi-disciplinary academic medical centre in Columbus, Ohio. Nines Inc, December 2019 – a $6m five-year deal with Palo Alto-based Nines that will see